TICKERNERD
Menu
BHVNBHVNHealthcare · Biotechnology

BHVN Stock Forecast: Biohaven Ltd. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$14
+2.52% on the day

The 17 Wall Street analysts covering Biohaven Ltd. hold a median 12-month price target of $20 — +44.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.1B
Ticker Nerd rank
24 / 100
Median analyst target
$20
Analysts covering
17
Total return, dividends reinvested
1W
−5.5%
1M
−10.8%
YTD
+22.6%
1Y
−5.7%
From 52W high
−23.6%
From 52W low
+77.7%
$8
$18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BHVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biohaven Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
79
Accruals
73
Value
42
Momentum
37
Size
36
Volatility
36
Revisions
30
Quality
17
Issuance
16

Growth (79): Sales and profits are climbing, and climbing faster than before.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BHVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BHVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26BHVNHigh $50Median $20Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
13 Buy3 Hold1 Sell
Low $10Median $20High $50

The green dot is the last close — the median target sits +44.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
12 Aug 2026Morgan StanleyMaintainsOverweight$18 → $19
11 Aug 2026RBC CapitalMaintainsOutperform$22 → $23
29 June 2026B of A SecuritiesDowngradeUnderperform$12 → $11
29 June 2026B of A SecuritiesDowngradeUnderperform—
26 May 2026HC Wainwright & Co.ReiteratesNeutral—
13 May 2026Morgan StanleyMaintainsOverweight—
5 May 2026RBC CapitalMaintainsOutperform—
2 Apr 2026CitigroupMaintainsBuy—
11 Mar 2026TD CowenMaintainsBuy—
4 Mar 2026HC Wainwright & Co.MaintainsNeutral—
3 Mar 2026RBC CapitalMaintainsOutperform—
21 Jan 2026RBC CapitalUpgradeOutperform—
6 Jan 2026Morgan StanleyMaintainsOverweight—
26 Dec 2025HC Wainwright & Co.ReiteratesNeutral—
3 Dec 2025HC Wainwright & Co.DowngradeNeutral—
26 Nov 2025UBSDowngradeNeutral—
20 Nov 2025JP MorganMaintainsOverweight—
18 Nov 2025BTIGReiteratesBuy—
18 Nov 2025Morgan StanleyMaintainsOverweight—
13 Nov 2025CitigroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHVN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BHVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
3
Fundamentals

Biohaven Ltd. (BHVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 85% of US stocks

Price / sales
—
Price / book
171.0×

Cheaper than 1% of US stocks

EV / EBITDA
−4.1×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−799.5%

Higher than 2% of US stocks

Return on assets
−72.0%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BHVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BHVNBiohaven Ltd.$2.1B
24
STOKStoke Therapeutics, Inc.$2.0B
55
PVLAPalvella Therapeutics, Inc.$2.0B
31
ZBIOZenas BioPharma, Inc.$2.0B
25
XNCRXencor, Inc.$2.0B
83
ZYMEZymeworks, Inc.$2.1B
72
SRPTSarepta Therapeutics, Inc.$2.0B
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biohaven Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BHVN news & analysis

Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results

PRNewsWire · 10 Aug 2026positive

Biohaven reported recent business developments and second quarter 2026 financial results, highlighting progress with its extracellular protein degrader platform. Clinical data from BHV-1300 in Graves' disease and BHV-1400 in IgA Nephropathy showed deep, rapid, and selective lowering of disease-driving antibodies in nearly 200 dosed individuals, and a pivotal Phase 3 study for BHV-1300 has been initiated, with a Phase 3 for BHV-1400 planned for the second half of 2026.

Why it matters — These developments mark the advancement of Biohaven's extracellular degrader platform toward potential registrational programs, which could shape the company's near-term clinical and regulatory pipeline.

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors

PRNewsWire · 6 Aug 2026neutral

Biohaven Ltd. announced the appointment of technology investor and Infinitum founder John Yetimoglu to its board of directors. Yetimoglu, a Groq board director, brings frontier AI and technology-investing expertise as Biohaven advances AI-enabled approaches to drug development.

Why it matters — A BHVN watcher would care because the appointment adds AI and technology-investing expertise directly relevant to Biohaven's AI-enabled drug development initiatives.

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million

PRNewsWire · 27 July 2026positive

A federal jury found that Avilar Therapeutics and RA Capital willfully and maliciously misappropriated a trade secret developed at Yale, and awarded Biohaven Ltd. and Yale University $4 million in damages.

Why it matters — The verdict affirms that Biohaven's intellectual property rights in a Yale-developed trade secret were violated, resulting in a monetary award and legal validation for Biohaven.

FAQ

Frequently asked questions about BHVN stock

What is the BHVN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Biohaven Ltd. have a median 12-month price target of $20, with estimates ranging from $10 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BHVN stock a buy right now?

Of the 17 analysts covering Biohaven Ltd., 13 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biohaven Ltd. 24 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BHVN?

As at 22 Aug 2026, Biohaven Ltd. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).

Will BHVN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +44.5% from the last close, and Ticker Nerd's factor model ranks Biohaven Ltd. 24 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BHVN stock forecast for 2030?

No analyst covering Biohaven Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $50 over the next 12 months.

How has BHVN stock performed over the past year?

Biohaven Ltd. returned -5.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biohaven Ltd. do?

Biohaven Ltd. is a clinical-stage biopharmaceutical company that focuses on creating novel therapies for neurological and neuropsychiatric diseases.

What is the latest news on BHVN?

The most recent item we track (PRNewsWire, 10 Aug 2026): "Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results". Biohaven reported recent business developments and second quarter 2026 financial results, highlighting progress with its extracellular protein degrader platform. Clinical data from BHV-1300 in Graves' disease and BHV-1400 in IgA Nephropathy showed deep, rapid, and selective lowering of disease-driving antibodies in nearly 200 dosed individuals, and a pivotal Phase 3 study for BHV-1300 has been initiated, with a Phase 3 for BHV-1400 planned for the second half of 2026.

Company

About Biohaven Ltd.

Biohaven Ltd. is a clinical-stage biopharmaceutical company that focuses on creating novel therapies for neurological and neuropsychiatric diseases. Its primary function is to develop innovative drugs that address unmet medical needs, particularly in critical areas such as migraine relief and neurodegenerative conditions. Biohaven Ltd. is notable for implementing advanced platforms in its research, such as calcitonin gene-related peptide (CGRP) receptor antagonists, which hold significant promise in treating migraines. The company also explores glutamate modulation, a pathway critical for various mental health disorders and neurological diseases. In the broader financial market, Biohaven Ltd. represents a critical component of the biotechnology and pharmaceutical sectors, driving advancements through cutting-edge research and a robust pipeline of therapeutic candidates. Headquartered in New Haven, Connecticut, Biohaven Ltd.'s innovative focus positions it as a prominent contender in addressing complex ailments, thereby holding substantial potential for impact within healthcare and related industries.

CEO Dr. Vladimir Coric M.D. · 274 employees · United States · https://www.biohaven.com